TRX and Sarcopenia: Biomarkers Shift Before Muscle Mass

Resistance exercise may improve how sarcopenic muscle functions before a body-composition scan can show more muscle. That is the useful, limited lesson from an eight-week trial of TRX suspension training in older men: participants improved functional measures and several blood biomarkers, while measured muscle mass did not change.

The finding fits a broader pattern, but the field remains small. A 2025 systematic review of exercise-induced biomarkers in sarcopenia found only six qualifying randomized controlled trials published from 2019 through 2025. That is enough to identify a few plausible signals. It is nowhere near enough to define an ideal program, predict an individual response, or turn a blood test into a scorecard for muscle growth.

What changes first when older muscle trains?

Sarcopenia involves loss of muscle strength, physical function, and muscle mass with age. Exercise can affect all three, but they do not move on the same timetable. Early strength gains often reflect changes in the nervous system: better motor-unit recruitment, more coordinated firing, and less opposing muscle activity during movement. Detectable hypertrophy generally takes longer, especially when the person begins with low muscle mass and the measurement itself has meaningful day-to-day variability.

Blood biomarkers offer a partial view of this early phase. The systematic review found that resistance training generally reduced inflammatory markers such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP) in older adults with confirmed sarcopenia. TNF-α and IL-6 each appeared in 57% of the six trials; CRP appeared in 29%.

The most internally consistent molecular pattern involved myostatin and follistatin. Myostatin restrains muscle growth signaling through the ActRIIB/Smad2/3 pathway, which can suppress downstream AKT/mTOR protein-synthesis signaling. Follistatin can bind and neutralize myostatin. Across the sparse sarcopenia literature, resistance exercise tended to lower myostatin and raise follistatin. Myostatin appeared in three of the six trials, making this the best-studied biomarker axis in the review—but three measurements are still a very small foundation.

These changes are biologically plausible, not proof that a particular change in myostatin or follistatin causes a person to gain muscle. A blood biomarker is a surrogate outcome. The outcomes that matter to patients are strength, walking, falls, independence, and eventually body composition where appropriate.

The TRX trial: improved biomarkers and function, unchanged muscle mass

A 2024 controlled clinical trial of TRX suspension training tested that idea in Iranian older men with sarcopenia. The experimental group included 19 men who completed eight weeks of TRX training, three sessions per week. The study was semi-experimental and did not blind participants or assessors, so it should be read as an early signal rather than a finished clinical answer.

After eight weeks, the TRX group had statistically significant reductions in myostatin and GDF-15, along with a statistically significant increase in follistatin. GDF-15 is a stress-responsive marker linked with mitochondrial dysfunction and systemic inflamm-aging. Participants also improved handgrip strength, gait speed, and Short Physical Performance Battery scores. The study reported no detectable change in appendicular skeletal muscle mass index or skeletal muscle mass.

That mismatch does not make the trial a failure. Eight weeks sits at the shortest end of the interventions in the systematic review, whose trials lasted 8 to 24 weeks, with an average duration of about 17 weeks. In older adults with sarcopenia, a small early gain in muscle tissue can fall below the test-retest variability of DXA or bioimpedance-based measurements. The absence of a measured mass change therefore cannot distinguish between no hypertrophy and hypertrophy too small to resolve over that interval.

It also does not prove that TRX reverses sarcopenia. The trial enrolled only men, used a small experimental group, and lacked blinding. Its use of Turkish handgrip cutoffs in an Iranian cohort adds another source of uncertainty. Women account for an estimated 60% to 70% of the global sarcopenia burden, so these results cannot stand in for the population as a whole.

Why bodyweight resistance remains plausible

TRX is not a substitute for evidence; it is one way to create progressive resistance by changing body angle, stability demands, range of motion, and mechanical advantage. The broader exercise literature supports the idea that sarcopenic muscle does not require only conventional heavy gym loading to improve.

For example, a 2024 randomized trial of low-load blood-flow-restriction training found that low-load resistance training at 20% to 50% of one-repetition maximum produced sarcopenia outcomes equivalent to conventional high-intensity resistance training above 70% of one-repetition maximum. That study did not test TRX and does not establish an equivalent dose for suspension training. It does show that lower external loads can still produce useful training stimuli in older adults with sarcopenia.

A 2023 network meta-analysis also found moderate-to-high-intensity resistance training effective for older adults with sarcopenia. A separate 2025 Bayesian network meta-analysis ranked combined aerobic and resistance training broadly best for functional outcomes. Those analyses focus on function, not biomarker changes, so they cannot validate the molecular claims made for TRX. They do provide useful context: exercise choice should prioritize a program an older adult can perform safely and sustain.

IGF-1 and exerkines need more restraint

IGF-1 has a cleaner public reputation than its evidence earns here. In the biomarker review, meaningful IGF-1 increases appeared with programs lasting at least six months that combined resistance and aerobic exercise. Short resistance-only interventions, including programs around eight weeks, did not reliably increase IGF-1. IGF-1 is therefore a poor short-term marker for judging whether an exercise program is working in sarcopenic older adults.

The evidence for irisin, brain-derived neurotrophic factor (BDNF), and other fashionable "exerkines" is thinner still. Irisin and BDNF each appeared in only one qualifying sarcopenia RCT in the review. There are no usable dose-response data, modality comparisons, or established links between shifts in these markers and patient outcomes in this population.

Young-adult findings do not repair that gap. A 2023 intervention study in young sedentary adults examined exercise-induced exerkine changes, but younger adults without sarcopenia are not a biological stand-in for people over 65 with low muscle mass and function. Claims that a specific exercise program will raise irisin or BDNF in sarcopenic older adults currently outrun the evidence.

Inflammation depends on the person being trained

The review's inflammatory signal is encouraging but not universal. In a 2025 resistance-training study in overweight and obese men, obesity attenuated inflammatory-marker responsiveness. Those participants were neither defined as sarcopenic nor elderly, so the result cannot quantify what will happen in sarcopenic people with obesity or metabolic syndrome. It does make the generalization problem plain: baseline metabolic health can change the size of an exercise-induced biomarker response.

Attrition adds another complication. Across the six trials in the systematic review, mean dropout was 17%, ranging from 0% to 43%. Exercise studies in older adults tend to retain people who can tolerate and adhere to the intervention, which can make results look better than what a less selected clinical population achieves.

What to do with this evidence

For an older adult with sarcopenia, resistance training remains a sensible core intervention. TRX or another bodyweight-based system can be a practical entry point when standard equipment is unavailable or heavy loading is poorly tolerated. The evidence supports treating it as progressive resistance exercise, not as a biomarker hack.

Give the program time. Eight weeks can be enough to detect functional and molecular movement; it is often too soon to make a confident call about muscle mass. A 12- to 24-week horizon is more reasonable for structural expectations, with progression tailored to ability and medical context. Nutrition also matters: a 2026 meta-analysis of nine RCTs involving 496 people with sarcopenia found that amino acid supplementation combined with resistance training improved handgrip strength and gait speed versus resistance training alone, though the authors rated the evidence low to very low certainty.

The practical verdict: train for strength and function first, reassess over months rather than weeks, and do not mistake an early biomarker shift for proof of muscle regrowth. The TRX result is promising enough to justify further trials, not confident enough to write a prescription.